Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mupirocin throat irrigation for persistent MRSA carriage
2014-005308-12Phase 2Completed
- Sponsor
- Region Sjælland
- Start
- Aug 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mupirocin in methicillin-resistant Staphylococcus aureus infection (MRSA) and Staphylococcal pharyngitis, sponsored by Region Sjælland. Primary endpoints: MRSA eradication at 1 month and Sustained MRSA eradication at ≥6 months. Started Aug 2018; status: completed.
02
Drugs
mupirocin
03
Conditions
methicillin-resistant Staphylococcus aureus infection (MRSA)Staphylococcal pharyngitis
Beyond the preview
Go deeper on 2014-005308-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005308-12.